

EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE



FOCUSMEETING.EANM.ORG

# EANM FOCUS 1

THE INTERNATIONAL  
CONFERENCE ON  
"MOLECULAR IMAGING  
AND THERANOSTICS  
IN PROSTATE CANCER"

FINAL PROGRAMME





# TABLE OF CONTENTS

Foreword .....	4
Overall Programme .....	6
Scientific Programme .....	
<b>Track 1</b> – February 1, 2018. ....	8
<b>Track 2</b> – February 1, 2018. ....	9
<b>Track 3</b> – February 2, 2018. ....	10
<b>Track 4</b> – February 2, 2018. ....	11
<b>Track 5</b> – February 3, 2018. ....	12
Panellists .....	14
General Information .....	28
Sponsors .....	31



## FOREWORD

The European Association of Nuclear Medicine (EANM), the world-leading society for nuclear medicine, molecular imaging and theranostics, is pleased to announce the EANM Focus Meeting – an annual conference in a new format that will take place in the first months of each year. It will supplement the very successful EANM Annual Congress in October and the educational events organised by EANM/ESMIT.





At the EANM Focus Meeting, a multidisciplinary group of experts and opinion leaders from all over the world will present state-of-the-art lectures and participate in consensus panels. The first EANM Focus Meeting will be on molecular imaging and theranostics in prostate cancer. We are very pleased that a large faculty of oncologists, urologists, imagers, clinical and basic scientists and patient-advocates has agreed to lecture and participate in the discussions. They will provide an in-depth overview of the current state of the art and future directions in the management of prostate cancer, with a focus on the role of imaging in general and nuclear medicine in particular, now and in the future. Based on the conference's results, a consensus statement will be produced. As the lectures and discussions will be at an advanced level and do not aim to provide basic overviews and education, the meeting will be particularly advantageous to clinicians who are already engaged in the diagnosis and treatment of prostate cancer.

We are welcoming you to the Focus Meeting – the new exciting EANM initiative.

With best personal regards,  
Wim J.G. Oyen and Stefano Fanti





## Thursday, February 1, 2018

07:30	Registration Desk Open
08:30 – 08:55	Opening
09:00 – 10:25	Track 1 - First Part
10:25 – 11:00	Coffee Break
11:00 – 13:00	Track 1 - Second Part
13:00 – 14:00	Lunch Break
14:00 – 15:25	Track 2 - First Part
15:25 – 16:00	Coffee Break
16:00 – 18:00	Track 2 - Second Part
18:00	Welcome Reception (at conference venue)

## Friday, February 2, 2018

08:00	Registration Desk Open
09:00 – 10:25	Track 3 - First Part
10:25 – 11:00	Coffee Break
11:00 – 13:00	Track 3 - Second Part
13:00 – 14:00	Lunch Break
14:00 – 15:25	Track 4 - First Part
15:25 – 16:00	Coffee Break
16:00 – 18:00	Track 4 - Second Part
19:30	Conference Dinner (at Marina Beach Club Restaurant) <i>Shuttle provided, please refer to General Information</i>

## Saturday, February 3, 2018

08:00	Registration Desk Open
09:00 – 10:40	Track 5 - First Part
10:40 – 11:00	Coffee Break
11:00 – 12:45	Track 5 - Second Part
12:45 – 13:00	Closing
13:00 – 14:00	Farewell Lunch (at conference venue)





# Oncology Courses 2018

Level  
2



**Spring School:**  
Oncology Track on  
Gynaecological  
malignancies  
May 4 – 6, 2018  
Ghent/BE

Level  
2



**Autumn School:**  
Oncology Track  
on Lymphoma  
September 7 – 9, 2018  
Belgrade/BE

Level  
3



**Interactive Course on  
Advanced Approach to  
Treatment Response  
Assessment in Oncology**  
November 22 – 23, 2018  
Vienna, Austria

Level  
3



**Interactive Course  
on PET/MR in  
Paediatric Oncology**  
December 10 – 11, 2018  
Vienna, Austria



Track

1

Thursday, February 1, 2018, 08:30 – 13:00

# Staging of High Risk Prostate Cancer

Chairpersons: Ken Herrmann, Jeroen van Moorselaar, Hebert Alberto Vargas

- |               |   |
|---------------|---|
| 08:30 – 08:55 | <b>Opening &amp; Objectives</b><br>Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT)                            |
| 09:00 – 09:25 | <b>Clinical Unmet Need at Staging</b><br>Jeroen van Moorselaar (Amsterdam, NL)                                    |
| 09:30 – 09:55 | <b>Contribution of Radiology for Staging Prostate Cancer</b><br>Hebert Alberto Vargas (New York, US)              |
| 10:00 – 10:25 | <b>Contribution of Nuclear Medicine for Staging Prostate Cancer</b><br>Ken Herrmann (Essen, DE)                   |
| 11:00 – 11:15 | <b>Controversy: Is there still a Role for CT and Bone Scan?</b><br>Howard Scher (New York, US)                    |
| 11:15 – 11:30 | <b>In Favour</b><br>Matthias Eiber (Munich, DE)   |
| 11:30 – 11:45 | <b>Against</b><br>Gerald Antoch (Düsseldorf, DE)  |
| 11:45 – 12:00 | <b>Questions &amp; Answers</b>  |
| 12:00 – 13:00 | <b>Consensus on Imaging for Staging HR Prostate Cancer</b><br>Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT) |

SCIENTIFIC PROGRAMME





Track

# 2

Thursday, February 1, 2018, 14:00 – 18:00

## Imaging of Biochemical Recurrence of Prostate Cancer

Chairpersons: Arturo Chiti, Johann de Bono, Bertrand Tombal

- |               |   |
|---------------|---|
| 14:00 – 14:25 | Clinical Unmet Need at Biochemical Recurrence of Prostate Cancer<br>Bertrand Tombal (Brussels, BE)                        |
| 14:30 – 14:55 | Contribution of Radiology at Biochemical Recurrence of Prostate Cancer<br>Frédéric Lecouvet (Brussels, BE)                |
| 15:00 – 15:25 | Contribution of Nuclear Medicine at Biochemical Recurrence of Prostate Cancer<br>Arturo Chiti (Milan, IT)                 |
| 16:00 – 16:15 | Controversy: Should we Address Biochemical Recurrence of Prostate Cancer asap?<br>Bertrand Tombal (Brussels, BE)          |
| 16:15 – 16:30 | In Favour<br>Hendrik van Poppel (Leuven, BE)  |
| 16:30 – 16:45 | Against<br>Johann de Bono (London, UK)  |
| 16:45 – 17:00 | Questions & Answers   |
| 17:00 – 18:00 | Consensus on Imaging for Biochemical Recurrence of Prostate Cancer<br>Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT) |

SCIENTIFIC PROGRAMME





Track

# 3

Friday, February 2, 2018, 09:00 – 13:00

## Imaging of Advanced Prostate Cancer (CRPC)

Chairpersons: Rodney Hicks, Joe O'Sullivan, Anwar Padhani

- |               |  |
|---------------|--|
| 09:00 – 09:25 | <b>Clinical Unmet Need of Advanced Prostate Cancer</b><br>Karim Fizazi (Paris, FR)                                     |
| 09:30 – 09:55 | <b>Contribution of Radiology in mCRPC</b><br>Anwar Padhani (London, UK)  |
| 10:00 – 10:25 | <b>Contribution of Nuclear Medicine in mCRPC</b><br>Rodney Hicks (Melbourne, AU)                                       |
| 11:00 – 11:15 | <b>Controversy: Do we Need Modern Imaging for Oligometastatic Prostate Cancer?</b><br>Jochen Walz (Marseille, FR)      |
| 11:15 – 11:30 | <b>In Favour</b><br>Rodney Hicks (Melbourne, AU)   |
| 11:30 – 11:45 | <b>Against</b><br>Joe O'Sullivan (Belfast, UK)   |
| 11:45 – 12:00 | <b>Questions &amp; Answers</b>   |
| 12:00 – 13:00 | <b>Consensus on Imaging of Advanced Prostate Cancer (mCRPC)</b><br>Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT) |





Track

# 4


Friday, February 2, 2018, 14:00 – 18:00

## Therapy of Advanced Prostate Cancer (mCRPC)

Chairpersons: Ignasi Carriò, Noel Clarke, Silke Gillesen

- |               |   |
|---------------|---|
| 14:00 – 14:25 | <b>Oncological Treatment of mCRPC</b><br>Silke Gillesen (St. Gallen, CH)  |
| 14:30 – 14:55 | <b>Radium-223 for Treatment of mCRPC</b><br>Noel Clarke (Manchester, UK)  |
| 15:00 – 15:25 | <b>PSMA Radioligands for Treatment of mCRPC</b><br>Uwe Haberkorn (Heidelberg, DE)   |
| 16:00 – 16:15 | <b>Controversy: Will Targeted Systemic Radiotherapy Become Clinical Practice?</b><br>Piet Ost (Ghent, BE)                   |
| 16:15 – 16:30 | <b>In Favour</b><br>Ignasi Carriò (Barcelona, ES)   |
| 16:30 – 16:45 | <b>Against</b><br>Noel Clarke (Manchester, UK)  |
| 16:45 – 17:00 | <b>Questions &amp; Answers</b>  |
| 17:00 – 18:00 | <b>Consensus on Targeted Systemic Radiotherapy of Advanced mCRPC</b><br>Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT) |

SCIENTIFIC PROGRAMME





Track

# 5

Saturday, February 3, 2018, 09:00 – 13:00

## New Prostate Cancer Targets for Imaging and Therapy

Chairpersons: Jack Schalken, Uwe Haberkorn

SCIENTIFIC PROGRAMME

09:00 – 09:20	<b>Potential New Pathways</b> Jack Schalken (Nijmegen, NL)
09:20 – 09:40	<b>Role of Prostate Cancer Genetics</b> Johann de Bono (London, UK)
09:40 – 10:00	<b>Pathologist's Perspective</b> Rudolfo Montironi (Ancona, IT)
10:00 – 10:20	<b>Radiopharmaceutical Developments</b> Hans-Jürgen Wester (Munich, DE)
10:20 – 10:40	<b>Perspective Discussion</b> Johann de Bono (London, UK)
11:00 – 11:20	<b>Patient's Perspective</b> Ian Banks (Ulster, UK)
11:20 – 11:40	<b>Foundation's Perspective</b> Sam Gledhill (Melbourne, AU)
11:40 – 12:00	<b>Consensus on Relevant Factors to Build a Consensus</b> all panellists (chairpersons: Stefano Fanti/Howard Scher)
12:00 – 12:45	<b>Summary on Results and Debate with all Participants</b> all panellists (chairpersons: Silke Gillessen/Wim Oyen)
12:45 – 13:00	<b>Future Directions &amp; Closing Remarks</b> Wim Oyen (London, UK) & Stefano Fanti (Bologna, IT)



# THE PANELLISTS

---

We kindly thank our panellists  
for their valuable support.





1

**Gerald Antoch**  
(Düsseldorf, DE)



**Professional Experience:**

1999-2000: Department of General and Trauma Surgery, Marien-Hospital Düsseldorf

2001-2010: Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen

2001-2004: Residency in Diagnostic and Interventional Radiology

2004: Board Certification in Radiology

2004-2008: Consultant Radiologist

2008-2010: Vice Chairman

since 2010: Chairman of the Department of Diagnostic and Interventional Radiology, University Hospital Düsseldorf

**Scientific Focus**

Hybrid Imaging

**Clinical Focus**

Hybrid Imaging

Interventional Radiology

2

**Ian Banks**  
(Ulster, UK)



He is the official spokesman on men's health issues for the BMA, president of the European Mens Health Forum and former president the England & Wales Men's Health Forum, past vice president of the International Society of Mens Health, past deputy editor of the Mens Health Journal and for six years the medical editor for The Men's Health Magazine. He has written over 150 books and manuals on health including the NHS Good Health Guide.

Ian was appointed visiting professor of mens health in Europe by Leeds Metropolitan University in 2005 and awarded the Royal Society of Public Health Gold Medal for public health in 2007 followed by appointment to the Academy in 2012. The City of Vienna and the International Society of Mens Health honoured Ian with their award for public health in September 2007. In 2012 the RSPH appointed Ian as Professorial Fellow to the Society. He is now visiting professor to the Universities of Ulster and Leeds along with honorary senior lecturer at Queens University medical school. He currently chairs the European Cancer Organisation (ECCO) patient advisory committee and the European Forum Against Blindness (EFAB). He was appointed vice president of the European Cancer Concord (ECC) in 2015.

3

**Ignasi Carriò**  
(Barcelona, ES)



Professor of Radiology and Nuclear Medicine at Autonomous University of Barcelona, and Director of the Department of Nuclear Medicine at Hospital Sant Pau in Barcelona, Spain.

Main research and scientific activity in Nuclear Medicine and Molecular Imaging, in particular in the fields of Oncology and Cardiovascular Medicine.

Editor-in-Chief of the European Journal of Nuclear Medicine and Molecular Imaging.

Former President of the European Association of Nuclear Medicine.

4

**Arturo Chiti**  
(Milan, IT)



Arturo Chiti graduated in Medicine and Surgery at the University of Milan in 1989, and entered the Training Program in Nuclear Medicine, where he got the certification in 1993.

In 1997, he got the European Board of Nuclear Medicine fellowship.

From June 2000, he is Director of Nuclear Medicine Department at the Humanitas Hospital.

On March 2015, he was appointed Full Professor in Diagnostic Imaging and Radiotherapy at the Humanitas University.

He is co-author of several papers and contributed to many abstracts presented at international and national meetings.

He is Editor in Chief of the EJ of Hybrid Imaging and Associate Editor of the EJNMMI.

He is a well-known invited speaker at numerous international congresses and conferences.

Arturo Chiti was the President 2015-16 of the EANM. Is a member of the ECCO Board and of ICRU.

He was awarded the honorary membership of ESTRO; the Tom Miller Memorial Lecture Award from SNMMI and the Hevesy Gyorgy award from the Hungarian Society of NM.





5

**Noel Clarke**  
(Manchester, UK)

5



Noel Clarke has been a Consultant Urological Surgeon at the Christie and Salford Royal Hospitals, Manchester, since 1993, and Honorary Professor of Urological Oncology at Manchester University since 2007. He completed his MBBS in London in 1981, his FRCS(Eng) in 1985, his ChM in Manchester 1990 and his urological accreditation and FRCS(Urol) in 1991. Since that time he has specialised in secondary and tertiary referral complex pelvic and retroperitoneal surgery research in to Genito-Urinary malignancy and the delivery of Cancer treatment. He is a nationally and internationally recognised expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney and testis in addition to providing regional and supra-regional surgical provision for complex and rare abdominal tumours such as abdominal / retro-peritoneal sarcoma's.

Professor Clarke has held the positions of Director of Urology at Salford Royal Hospitals and Director of Surgery at the Christie Hospital, and he coordinated the development of Manchester and Cheshire Urological Cancer Network between 2002 and 2010. He was Chairman of the UK National Cancer Research Institute Prostate Clinical Studies Group between 2003 and 2009, Co-Chairman of the EORTC GU group and was one of 2 Urologists involved in development and publication of the "Improving Outcomes Guidance". He is currently Director of the Manchester University GU Cancer Research Group, the pan-Manchester biobank and clinical lead for the Manchester / Belfast FASTMAN national centre of Excellence for prostate cancer research and for the National Prostate Cancer Audit in England and Wales.

6

**Johann de Bono**  
(Sutton, UK)

6



Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is also the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. Additionally he leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team.

He has been involved in the development of many novel agents, many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts including multiple publications in the New England Journal of Medicine and The Lancet.

7

**Matthias Eiber**  
(Munich/DE)

7



Matthias Eiber is board certified radiologist and nuclear medicine physician who was trained at the Institute of Radiology and the Department of Nuclear Medicine at Technical University Munich. After a research fellowship at the Ahmanson Translational Imaging Division in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) he is currently working as attending and assistant professor at the Department of Nuclear Medicine at the Technical University Munich. His main research activity is currently focused on hybrid imaging and prostate cancer theranostics especially the application of prostate specific membrane antigen (PSMA) ligands for imaging, radioguided surgery as well for endoradiotherapy in castration-resistant prostate cancer.

8

**Stefano Fanti**  
(Bologna/IT)

8



Born in Bologna, Italy, where completed all his studies and graduated at University of Bologna. Started working in conventional nuclear medicine in the '90, then involved in the project of PET Unit at S.Orsola Policlinic Hospital, participating to site planning then appointed as medical director in 2002. Last year the PET Unit carried out more than 12000 exams, resulting one of the most active in Europe; in particular the PET Center in Bologna is known for the nonFDG scans, in both clinical routine and research area (about 2000 exams last year).

At present he is full time employed in Nuclear Medicine as Professor of Diagnostic Imaging as well as Director of Nuclear Medicine Division and of PET Unit at the S.Orsola Policlinic Hospital. Author of more than 350 full articles published in peer reviewed international journals, several books and chapters; invited lecturer at more than 120 national and international meetings.

Chair of the Oncology Committee of EANM.



9

## Karim Fizazi

(Paris, FR)



K Fizazi, MD, PhD, is a medical oncologist, head of the Department of Cancer Medicine at the Institute Gustave Roussy, and full professor in Oncology at the University of Paris Sud in Villejuif, France.

He has authored numerous abstracts at international congresses and has published over 291 peer-reviewed articles.

Amongst his major achievements, Prof. Fizazi was first to establish the role of early chemotherapy in order to prevent relapse in high-risk localized prostate cancer in the GETUG 12 trial. Prof. Fizazi demonstrated the role of denosumab, for the prevention of complications of bony metastases from prostate cancer. In testicular cancer, Prof. Fizazi could establish in 2014 with the GETUG 13 trial a new standard of care for young patients with poor-prognosis metastatic cancer, thanks to an individualized algorithm of treatment.

Prof Fizazi is involved in many phase I, II, and III clinical trials as a national or global coordinating investigator, including the cabozantinib Comet-1, the abiraterone M1 Latitude, the cabazitaxel-OGX-011 Affinity and the CRPC M0 ODM-201 Aramis large phase III trials in prostate cancer. Prof. Fizazi created in 2013 the Prostate Cancer Consortium in Europe (PEACE). He's now head of the two first PEACE large European academic phase III trials: PEACE-1 (testing abiraterone and radiotherapy to local primary cancer in de novo metastatic prostate cancer) and PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localized prostate cancer).

10

## Silke Gillesen

(St. Gallen, CH)



Prof. Silke Gillesen Sommer, MD, is a senior consultant, specializing in genitourinary tumors, in the Department of Oncology/Hematology at Kantonsspital St. Gallen, St. Gallen, Switzerland, where she also heads the Clinical Trial Unit.

She is a member of several professional societies. From 2007 to 2013, she was president of the SAKK Project Group on Urogenital Tumors.

She is currently the Chair of the EORTC Genito-Urinary Cancers Group.

She served/serves on the ESMO Scientific Subcommittees for GU Oncology 2014/2015/2016. 2017 she became chair of Scientific Subcommittee for Genitourinary tumours (Prostate) for ESMO 2018. From 2016 she is a Member of the ESMO guidelines Committee as deputy for GU malignancies

She is one of the organizers of the St.Gallen Advanced Prostate Cancer Consensus Conference (APCCC) held in 2015 and 2017.

13

**Ken Herrmann**  
(Essen, DE)



Ken Herrmann is a board certified Nuclear Medicine physician who was trained in the group of Markus Schwaiger at TUM, Germany. He received a MBA degree from University Zürich in 2011. From 2012 to 2016 he served as Vice Chair of Nuclear Medicine at the University of Würzburg. In 2011 Ken Herrmann was added to the faculty of the Ahmanson Translational Imaging Division in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). In 2015 he was tenured at UCLA. Since August 2016 Ken Herrmann is Chair of Nuclear Medicine at Universitätsklinikum Essen, Germany, and serves as Adjunct Professor in the Department of Molecular and Medical Pharmacology at UCLA.

His research focus includes hybrid imaging modalities as well as receptor targeted theranostics with a special focus on prostate cancer. As part of the EANM Oncology Committee he is also involved in the recently published procedure guideline of  $^{68}\text{Ga}$ -PSMA PET imaging in prostate cancer.

14

**Rodney Hicks**  
(Melbourne, AU)



Rod is a Professorial Fellow of the University of Melbourne and Director of Cancer Imaging at the Peter MacCallum Cancer Centre. Peter Mac installed the first PET/CT outside Europe and North America in 2001 and established the first pre-clinical PET imaging facility in Australia in 2002 enabling a strong focus on translational research. He is actively involved in the therapeutic uses of nuclear medicine, especially for the treatment of neuroendocrine tumours. He holds numerous national and international research grants and is Editor-in-Chief of Cancer Imaging, as well as serving on 6 other editorial boards including Endocrine-Related Cancer. He has over 400 peer-reviewed publications with over 16,000 citations. He received a prestigious National Health and Medical Research Council Program Grant in 2013 and NHMRC Practitioner Fellowship in 2015. He was also inducted as a Fellow of the Australian Academy of Health and Medical Science in 2015.



11

**Sam Gledhill**  
(Melbourne, AU)



A qualified Nuclear Medicine Technologist, Sam has over a decade of experience in clinical Nuclear Medicine as well as post graduate qualifications in Statistics and an MBA. Sam has worked across the public and private health system in clinical, research and management roles and has spent the last 5 years managing a number of biomedical research projects at the Movember Foundation.

Sam has overarching responsibility for the delivery of the Movember GAP Program, a portfolio of several globally collaborative projects in Prostate and Testicular Cancer Translational Research. One of the early projects in the GAP portfolio is the GAP2 Imaging in Advanced Prostate Cancer project. The GAP2 project was commenced in 2013 and finished in early 2017 and focussed on the development and validation of new-generation tracers to better detect prostate disease as it progresses.

12

**Uwe Haberkorn**  
(Heidelberg, DE)



12

**1979-82:** Studies in Philosophy and german literature at the university of Heidelberg

**1982-88:** Studies in medicine at the universities of Marburg, Würzburg and Heidelberg

**1988-98:** Research physician at the department of Oncological Diagnostics and therapy at the Deutsches Krebsforschungszentrum Heidelberg

**since 1998** Professor of Nuclear medicine at the university of Heidelberg, Head of the Dept. of Nuclear Medicine, University of Heidelberg, Head of the Clinical Cooperation Unit Nuclear Medicine at the Deutsches Krebsforschungszentrum Heidelberg

Editorial board member of Molecular Imaging and Biology, European Journal of Nuclear medicine and Molecular Imaging, Nuklearmedizin, Journal of Nuclear Medicine; Member of SABs Institute for Dutch Cancer Society, DFG, MRC Medical Research Council London UK, Institut national de la sante et de la recherche medicale, Institut national du cancer Paris, Mildred Scheel Foundation, Agence national de la Recherche France



15

## Frédéric Lecouvet

(Brussels, BE)

15



Frederic Lecouvet has been a Full Professor of Radiology at the Radiology Department at Cliniques Universitaires Saint-Luc in Brussels, Belgium, since 2008.

He completed both his medical training (1992) and PhD (1998) at the Université Catholique de Louvain (UCL), Brussels, Belgium.

He is currently associate chair of the Department of Medical imaging, head of the MRI unit, chair of the Imaging Research Pole of the Institut de Recherche Experimentale et Clinique Research at the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

His areas of expertise include imaging of bones, spine, joints, and development of modern imaging techniques to improve the work-up and the assessment of the response to treatment in lesions affecting these organs, particularly bone tumors and metastases.

He authored more than 180 peer reviewed papers, 30 book chapters, 6 books, and gave more than 300 international lectures. He is an elected member of the Royal Academy of Medicine of Belgium.

16

## Rodolfo Montironi

(Ancona, IT)



16

Rodolfo Montironi, MD and IFCAP, obtained his medical degree at the Medical School of the University of Ancona, Italy in 1976, the board certificate in pathology and laboratory medicine at the University of Parma, Italy, in 1979, and the board certificate in clinical oncology at the University of Ancona in 1982. He is International Fellow of the College of American Pathologists. He is Professor of Pathology at the Medical School of the Polytechnic University of the Marche Region, and, Director of the Uropathology Program, United Hospitals, Ancona, Italy. He is a Past President of the International Society of Urological Pathology. He is the Chairman of the ESUP (EAU Section of Uropathology). He is a member of different international societies of pathology and of urology. Dr Montironi's work is centered in genitourinary tumor pathology. He is an author or coauthor of more than 700 publications in peer-reviewed international journals.



17

**Joe O'Sullivan**  
(Belfast, UK)



Joe O'Sullivan is Clinical Director of the Northern Ireland Cancer Centre, Belfast where he works as a Prostate Cancer Oncologist, and Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology, Queen's University Belfast.

Joe graduated from University College Dublin medical School in 1993 and trained in Radiation Oncology in St. Luke's Hospital in Dublin. In 2000 he took up a Clinical research Fellowship at the Royal Marsden London, completing a Doctorate Thesis on the use of high doses of Rhenium-186HEDP with stem cell support in advanced prostate cancer. He was appointed as a senior lecturer and consultant clinical oncologist to Queen's University Belfast in 2004 and was subsequently appointed as Professor of Radiation Oncology in 2011. He was appointed as Clinical Director of Oncology at The Northern Ireland Cancer Centre, Belfast in 2014.

His research interests include bone-seeking radionuclide therapy in metastatic prostate cancer, translational research in prostate cancer and radiotherapy, and clinical trials in advanced prostate cancer and he has published over 100 research papers. He is one the 4 Directors of the FASTMAN Prostate Cancer Centre of Excellence (Belfast and Manchester) which is 5-year programme of research awarded in 2014 and funded by Movember and PCUK.

18

**Piet Ost**  
(Ghent, BE)



Prof. Dr. Ost started his residency in radiation oncology at Ghent University Hospital in 2006. The pioneering position of the Department in the development of novel radiotherapy techniques such as intensity-modulated radiotherapy inspired him to focus his PhD research on the clinical implementation of these techniques in prostate cancer (PCa). He is currently employed at Ghent University Hospital as adjunct chief of clinic and as assistant professor at Ghent University. His research shifted to two main topics: treatment of oligometastatic prostate cancer and the influence of radiotherapy on the immune system.

19

**Wim Oyen**  
(London, UK)



Professor Wim Oyen was appointed Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital London, UK in 2015. Before he was Professor of Nuclear Medicine at the Radboud UMC Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine and Director of the Research Institute for Oncology.

His main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-) author of more than 600 articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (President-elect, past-Congress Chair), the European Cancer Organisation (Past-Treasurer), the International Cancer Imaging Society (President-elect). He is a member of the Editorial Board of The Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.

20

**Anwar Padhani**  
(London, UK)



Consultant Radiologist Prof. Anwar Padhani MB BS FRCP FRCR is an internationally recognized Oncological MRI radiologist and currently, the clinical lead in MRI at the Paul Strickland Scanner Centre. He is Professor of Cancer Imaging at the Institute of Cancer Research, London. He is specialist in the clinical evaluation of advanced MRI including dynamic MRI, diffusion weighted MRI, MR spectroscopy, whole body MRI and multiparametric MRI of the prostate for primary and metastatic disease. He has a passion for teaching and has published chapters in 31 textbooks, 64 educational and scientific journal reviews in peer reviewed journals, and published over 103 full scientific articles in peer reviewed journals. Prof. Padhani has given over 250 invited lectures at national and international, scientific and educational meetings including several plenary talks. He has to his credit several education related awards including outstanding teacher award from the ISMRM and RSNA.



21

**Jack Schalken**  
(Nijmegen, NL)

21



Jack A Schalken PhD (1959) has an appointment as professor of experimental urology at Radboud University MC, Nijmegen. Dr Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was (co) appointed as professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).

His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes

1. Unravelling the mechanism of (GU) cancer invasion/cadherin switching/EMT
2. Cancer stem/initiating cells
3. Targeted therapy in (GU) cancer
4. Molecular diagnostics (eg PCA3, SelectMDx)
5. Combining 1 thru 4 to make steps towards precision medicine

22

**Howard Scher**  
(New York, US)

22



Howard I. Scher, MD is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher's research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence.

23

## Bertrand Tombal

(Brussels, BE)



Professor Bertrand Tombal is Chairman of the Division of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium.

He is the current chairman of the Clinical Trial Division of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer.

He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. B. Tombal obtained his MD in 1990 and his PhD in 2003, both from the UCL. B. Tombal's primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area.

24

## Jeroen van Moorselaar

(Amsterdam, NL)



Jeroen van Moorselaar studied medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. In 1991 he obtained his PhD degree on 'Cytokine Therapy in Experimental Urological Cancer'. He was certified as urologist in June 1997. From that time he has worked in the University Hospital in Nijmegen in the urological department and in April 1998 he moved to the University Hospital in Utrecht where he worked until August 2005. In September 2005 he became the head of the urological outpatient department at the VU University Medical Centre in Amsterdam where he still works, but since August 2008 in the position of Chairman. In March 2011 he was appointed as Professor of Urology. He is member of various national and international organizations. He is member of the Dutch working party on urological oncological guidelines and is founding member of the Dutch UroOncology Study group. Since May 2007 he is board member of the European School of Urology. Furthermore he is member of the Examination Committee of the European Board of Urology. He is an active researcher in the field of urological oncology.





25

**Hendrik Van Poppel**  
(Leuven, BE)



H. Van Poppel, MD, PhD, graduated in General Surgery in 1980, in Urology in 1983 and joined the Academic Unit at KU Leuven in 1985 after his postgraduate training in London, Barcelona, Copenhagen, Mainz and Rotterdam. In 1988, he obtained a PhD in Medical Sciences. He became a Fellow of the European Board of Urology (FEBU) in 1992, full Professor of Urology in 1993, and chair of the department of urology in Leuven in 2002. He was visiting Professor in several countries all over the world, where he demonstrated live uro-oncologic surgery for kidney, bladder and prostate cancer.

He described the original surgical technique for prepubic urethrectomy, percutaneous gastrotomy, lumbar splenectomy during orthotopic kidney transplantation, and of the Leuven "N"pouch for bladder substitution and performed more than 2500 radical prostatectomies

He has published 209 papers as first author on uro-oncology and has co-authored more than 370 and (co-)edited several books on kidney / prostate cancer

26

**Hebert Alberto Vargas**  
(New York, US)



Dr. Vargas is a specialist in Oncologic and Molecular Imaging, currently the Director of Genitourinary Radiology at Memorial Sloan Kettering Cancer Center in New York. His clinical and research interests focus on the use of advanced imaging modalities, including diffusion-weighted and dynamic contrast-enhanced MRI and novel PET tracers for the non-invasive diagnosis, staging, treatment response assessment and follow-up of patients with cancer. Dr. Vargas is especially interested in imaging of patients with cancers involving the urinary system (e.g. prostate, bladder, and kidneys) and the female reproductive organs (e.g. uterus and ovaries).



27

## Jochen Walz

(Marseille, FR)



Assistant Professor Urology  
MD  
Master of Arts in management of health care institutions  
FEBU  
Board certified Urologist  
Research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montréal /Canada  
Residency: University of Hamburg/Germany and Marseille/France  
Medical School: University of Mainz/Germany

### Professional Experience/Appointments:

Head of Urology, Institut Paoli-Calmettes Cancer Centre  
Former Chairman EAU Section of Urological Imaging (ESUI)  
Main activity in Urooncology

### Research interests:

- Imaging in Urology
- Prostate cancer:
  - Imaging and Diagnosis
  - Prediction tools
  - Life expectancy
  - Surgical treatment
- Minimal invasive surgery

28

## Hans-Jürgen Wester

(Munich, DE)



H.J.P. Wester studied chemistry/radiochemistry and carried out his PhD thesis in Radiopharm. Chem. at the Res. Center Jülich (G. Stöcklin). In 2006, he started his research activities at the Technical University Munich at the Department Nuclear Medicine (M.Schwaiger). Today, he is full professor for Pharm. Radiochem. at the Technical University Munich. Some prominent tracers developed in his group are F-18-FET, RGD-peptides, F-18-DPN, Pentixafor, Pentixather, Avebetrin, Ga-68 labeled TRAP complexes, PSMA I&T and PSMA I&S. He was member of the Board of the German Society of Nuclear Medicine, is member of the Board of the Bavarian Society of Nuclear Medicine and co-speaker of the Collaborative Research Center SFB824 of the German Research Foundation. He is founder of SCINTOMICS (2006), was CEO until 07/2015 and is now member of the advisory board. His main interest is the development and transfer of innovative diagnostic and therapeutic radiopharmaceuticals, i.e. peptides.



## VENUE ADDRESS

SH Valencia Palace  
Passeig de l'Albereda, 32 / Paseo Alameda, 32  
46023 València

## REGISTRATION DESK OPENINGS

Thursday, February 1	07:30 - 18:00
Friday, February 2	08:00 - 18:00
Saturday, February 3	08:00 - 13:00

## CME CREDITS

The EANM Focus 1 : The International Conference on "Molecular Imaging and Theranostics in Prostate Cancer", Valencia, Spain, 01/02/2018-03/02/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **15 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The CME certificate will be sent out via e-Mail to all participants who have filled out and returned the evaluation sheet.

## CONFIRMATION OF ATTENDANCE

All participants will receive a Certificate of Attendance via e-Mail after the meeting.



## CONFERENCE DINNER

The conference dinner is going to take place on February 2, 2018 at 20:00 at the Marina Beach Club in Valencia. At 19:30 there will be a bus transfer from the SH Valencia Palace directly to the restaurant. Starting from 22:30 until 24:00 there will be a shuttle service every approx. 15 minutes back to the hotel.

**Location:** Marina Beach Club Valencia, Marina Real Juan Carlos I, 46011, Valencia

## FOOD & BEVERAGES

During the conference, coffee breaks will be provided to all participants. On Thursday night and Saturday noon, during the Welcome Reception and the Farewell Lunch, complimentary food and drinks will be served.

On Friday night, EANM invites all participants to join the complimentary Conference Dinner (please refer to "Conference Dinner" above).

## MEDIA

By attending the event, each participant acknowledges and agrees to grant EANM the right at the Focus Meeting to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed, and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to such participant or any of its representatives.

## NAME BADGES

The name badges must be worn at all times during the conference as we are in a hotel together with other guests. Persons without a name badge will be asked to leave the conference rooms.

## RECORDING OF SESSIONS

The meeting will be recorded and important parts will be made available online at the EANM/ESMIT eLearning Platform (<https://nedus.netkey.at/eanm/>) after the meeting once the production is finalized.



# SPONSORS

We kindly thank the following companies  
for their sponsorship engagement:

## Platinum Sponsors



Bayer



**BLUE EARTH**  
D I A G N O S T I C S

Blue Earth Diagnostics



GE Healthcare

GE Healthcare

## Gold Sponsors

**Progenics**  
Pharmaceuticals®  
*Find Fight and Follow™*

Progenics Pharmaceuticals, Inc.

**SIEMENS**  
**Healthineers**

Siemens Healthineers




Telix Pharmaceuticals



# EANM'18

WORLD LEADING MEETING



## Annual Congress of the European Association of Nuclear Medicine

October 13 – 17, 2018  
Düsseldorf, Germany

[eanm18.eanm.org](http://eanm18.eanm.org)



Visit us on  
[.com/officialEANM](https://www.facebook.com/officialEANM)



**FOCUSMEETING.EANM.ORG**

European Association of Nuclear Medicine  
Schmalzhofgasse 26 / Top 5  
1060 Vienna, Austria